目次

TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations

3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Techniques
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation

4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities

5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Demand and Supply
5.3.3. Regional Impact
5.3.4. Impact on R&D

6. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET, BY VECTOR TYPE
6.1. Overview
6.2. Plasmid DNA
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.3. Viral Vector
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
6.4. Non-Viral Vector
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027

7. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE
7.1. Overview
7.2. Upstream Processing
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
7.3. Downstream Processing
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027

8. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION
8.1. Overview
8.2. Antisense & RNAi Therapy
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
8.3. Gene Therapy
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
8.4. Cell Therapy
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
8.5. Vaccinology
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
8.6. Research
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027

9. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE
9.1. Overview
9.2. Cancer
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
9.3. Genetic Disorders
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
9.4. Infectious Diseases
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
9.5. Others
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027

10. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER
10.1. Overview
10.2. Pharmaceutical and Biopharmaceutical Companies
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027
10.3. Research Institutes
Market Estimates & Forecast, by Region, 2018-2027
Market Estimates & Forecast, by Country, 2018-2027

11. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET, BY REGION
11.1. Overview
11.2. North America
11.2.1. US
11.2.2. Canada
11.3. Europe
11.3.1. Germany
11.3.2. France
11.3.3. Italy
11.3.4. Spain
11.3.5. UK
11.3.6. Rest of Europe
11.4. Asia-Pacific
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Rest of the World
11.5.1. Middle East
11.5.2. Africa
11.5.3. Latin America

12. COMPANY LANDSCAPE
12.1. Overview
12.2. Competitive Analysis
12.3. Market Share Analysis
12.4. Major Growth Strategy in the Global Viral Vectors And Plasmid DNA ManufacturingMarket
12.5. Competitive Benchmarking
12.6. Leading Players in Terms of Number of Developments in the Global Viral Vectors And Plasmid Dna ManufacturingMarket
12.7. Key developments and Growth Strategies
12.7.1. New Product Launch/Service Deployment
12.7.2. Merger &Acquisitions
12.7.3. Joint Ventures
12.8. Major Players Financial Matrix
12.8.1. Sales & Operating Inc.ome, 2020
12.8.2. Major Players R&D Expenditure, 2020

13. COMPANY PROFILES
13.1. Cognate BioservicesInc.
13.1.1. Company Overview
13.1.2. Products Offered
13.1.3. Financial Overview
13.1.4. Key Developments
13.1.5. SWOT Analysis
13.1.6. Key Strategies
13.2. Catalent Pharma Solutions
13.2.1. Company Overview
13.2.2. Products Offered
13.2.3. Financial Overview
13.2.4. Key Developments
13.2.5. SWOT Analysis
13.2.6. Key Strategies
13.3. Fujifilm Holdings Corporation
13.3.1. Company Overview
13.3.2. Products Offered
13.3.3. Financial Overview
13.3.4. Key Developments
13.3.5. SWOT Analysis
13.3.6. Key Strategies
13.4. Johnson & Johnson
13.4.1. Company Overview
13.4.2. Products Offered
13.4.3. Financial Overview
13.4.4. Key Developments
13.4.5. SWOT Analysis
13.4.6. Key Strategies
13.5. Sanofi Corporation
13.5.1. Company Overview
13.5.2. Products Offered
13.5.3. Financial Overview
13.5.4. Key Developments
13.5.5. SWOT Analysis
13.5.6. Key Strategies
13.6. F-Hoffman LA Roche Ltd
13.6.1. Company Overview
13.6.2. Products Offered
13.6.3. Financial Overview
13.6.4. Key Developments
13.6.5. SWOT Analysis
13.6.6. Key Strategies
13.7. 4D Molecular Therapeutics
13.7.1. Company Overview
13.7.2. Products Offered
13.7.3. Financial Overview
13.7.4. Key Developments
13.7.5. SWOT Analysis
13.7.6. Key Strategies
13.8. Sirion Biotech GmbH
13.8.1. Company Overview
13.8.2. Products Offered
13.8.3. Financial Overview
13.8.4. Key Developments
13.8.5. SWOT Analysis
13.8.6. Key Strategies
13.9. Voyager Therapeutics
13.9.1. Company Overview
13.9.2. Products Offered
13.9.3. Financial Overview
13.9.4. Key Developments
13.9.5. SWOT Analysis
13.9.6. Key Strategies
13.10. Thermo Fisher Scientific
13.10.1. Company Overview
13.10.2. Products Offered
13.10.3. Financial Overview
13.10.4. Key Developments
13.10.5. SWOT Analysis
13.10.6. Key Strategies
13.11. Gene Therapy Catapult
13.11.1. Company Overview
13.11.2. Products Offered
13.11.3. Financial Overview
13.11.4. Key Developments
13.11.5. SWOT Analysis
13.11.6. Key Strategies
13.12. Uniqure
13.12.1. Company Overview
13.12.2. Products Offered
13.12.3. Financial Overview
13.12.4. Key Developments
13.12.5. SWOT Analysis
13.12.6. Key Strategies
13.13. Mass Biologics
13.13.1. Company Overview
13.13.2. Products Offered
13.13.3. Financial Overview
13.13.4. Key Developments
13.13.5. SWOT Analysis
13.13.6. Key Strategies
13.14. Renova Therapeutics
13.14.1. Company Overview
13.14.2. Products Offered
13.14.3. Financial Overview
13.14.4. Key Developments
13.14.5. SWOT Analysis
13.14.6. Key Strategies
13.15. Shenzhen SiBionoGeneTech Co., Ltd
13.15.1. Company Overview
13.15.2. Products Offered
13.15.3. Financial Overview
13.15.4. Key Developments
13.15.5. SWOT Analysis
13.15.6. Key Strategies

14. APPENDIX
14.1. References
14.2. Related Reports

LIST OF TABLES
TABLE 1 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET SYNOPSIS, 2018-2027
TABLE 2 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET ESTIMATES &FORECAST, 2018-2027(USD MILLION)
TABLE 3 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET, BYVECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 4 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 5 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 6 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 7 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 8 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 9 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 10 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 11 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 12 NORTH AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 13 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 14 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 15 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 16 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 17 USVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION)
TABLE 18 CANADAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 19 CANADAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 20 CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 21 CANADAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 22 CANADAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 23 EUROPE: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 24 EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 25 EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 26 EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 27 EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 28 GERMANY: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 29 GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 30 GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 31 GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 32 GERMANYVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 33 UK: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 34 UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 35 UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 36 UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 37 UKVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 38 FRANCE: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 39 FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 40 FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 41 FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 42 FRANCEVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 43 ITALY: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 44 ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 45 ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 46 ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 47 ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 48 SPAIN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 49 SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 50 SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 51 SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 52 SPAINVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 53 REST OF EUROPE: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 54 REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 55 REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 56 REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 57 REST OF EUROPEVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 58 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 59 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 60 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 61 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 62 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 63 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 64 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 65 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 66 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 67 INDIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 68 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 69 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 70 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 71 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 72 CHINA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 73 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 74 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 75 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 76 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 77 JAPAN: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 78 SOUTH KOREAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 79 SOUTH KOREA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 80 SOUTH KOREA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 81 SOUTH KOREA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 82 SOUTH KOREA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 83 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 84 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 85 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 86 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 87 AUSTRALIA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 88 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 89 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 90 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 91 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 92 REST OF ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 93 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 94 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 95 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 96 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 97 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 98 MIDDLE EAST: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 99 MIDDLE EAST: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 100 MIDDLE EAST: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 101 MIDDLE EAST: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER TYPE, 2018-2027 (USD MILLION)
TABLE 102 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 103 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 104 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 105 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 106 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 107 AFRICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 108 AFRICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 109 AFRICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 110 AFRICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 111 AFRICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION
TABLE 112 LATIN AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2018-2027 (USD MILLION)
TABLE 113 LATIN AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW TYPE, 2018-2027 (USD MILLION)
TABLE 114 LATIN AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)
TABLE 115 LATIN AMERICAVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2018-2027 (USD MILLION)
TABLE 116 LATIN AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2018-2027 (USD MILLION

LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET
FIGURE 4 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURINGMARKET SHARE, BY VECTOR TYPE, 2020 (%)
FIGURE 5 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY APPLICATION, 2020 (%)
FIGURE 6 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 NORTH AMERICA: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)
FIGURE 8 EUROPE: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)
FIGURE 9 ASIA-PACIFIC: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 REST OF THE WORLD: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SHARE, BY REGION, 2020 (%)
FIGURE 11 GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 12 COGNATE BIOSERVICES, INC.: KEY FINANCIALS
FIGURE 13 COGNATE BIOSERVICES, INC.: SEGMENTAL REVENUE
FIGURE 14 COGNATE BIOSERVICES, INC.: REGIONAL REVENUE
FIGURE 15 CATALENT PHARMA SOLUTIONS: KEY FINANCIALS
FIGURE 16 CATALENT PHARMA SOLUTIONS: SEGMENTAL REVENUE
FIGURE 17 CATALENT PHARMA SOLUTIONS: REGIONAL REVENUE
FIGURE 18 FUJIFILM HOLDINGS CORPORATION: KEY FINANCIALS
FIGURE 19 FUJIFILM HOLDINGS CORPORATION: SEGMENTAL REVENUE
FIGURE 20 FUJIFILM HOLDINGS CORPORATION: REGIONAL REVENUE
FIGURE 21 JOHNSON & JOHNSON: KEY FINANCIALS
FIGURE 22 JOHNSON & JOHNSON: SEGMENTAL REVENUE
FIGURE 23 JOHNSON & JOHNSON: REGIONAL REVENUE
FIGURE 24 SANOFI CORPORATION: KEY FINANCIALS
FIGURE 25 SANOFI CORPORATION: SEGMENTAL REVENUE
FIGURE 26 SANOFI CORPORATION: REGIONAL REVENUE
FIGURE 27 F. HOFFMANN-LA ROCHE LTD: KEY FINANCIALS
FIGURE 28 F. HOFFMANN-LA ROCHE LTD: SEGMENTAL REVENUE
FIGURE 29 F. HOFFMANN-LA ROCHE LTD: REGIONAL REVENUE
FIGURE 30 4D MOLECULAR THERAPEUTICS: KEY FINANCIALS
FIGURE 31 4D MOLECULAR THERAPEUTICS: SEGMENTAL REVENUE
FIGURE 32 4D MOLECULAR THERAPEUTICS: REGIONAL REVENUE
FIGURE 33 SIRION BIOTECH GMBH: KEY FINANCIALS
FIGURE 34 SIRION BIOTECH GMBH: SEGMENTAL REVENUE
FIGURE 35 SIRION BIOTECH GMBH: REGIONAL REVENUE
FIGURE 36 VOYAGER THERAPEUTICS: KEY FINANCIALS
FIGURE 37 VOYAGER THERAPEUTICS: SEGMENTAL REVENUE
FIGURE 38 VOYAGER THERAPEUTICS: REGIONAL REVENUE
FIGURE 39 THERMO FISHER SCIENTIFIC, INC.: KEY FINANCIALS
FIGURE 40 THERMO FISHER SCIENTIFIC, INC.: SEGMENTAL REVENUE
FIGURE 41 THERMO FISHER SCIENTIFIC, INC.: REGIONAL REVENUE
FIGURE 42 GENE THERAPY CATAPULT: KEY FINANCIALS
FIGURE 43 GENE THERAPY CATAPULT: SEGMENTAL REVENUE
FIGURE 44 GENE THERAPY CATAPULT: REGIONAL REVENUE
FIGURE 45 UNIQURE: KEY FINANCIALS
FIGURE 46 UNIQURE: SEGMENTAL REVENUE
FIGURE 47 UNIQURE: REGIONAL REVENUE
FIGURE 48 MASSBIOLOGICS: KEY FINANCIALS
FIGURE 49 MASSBIOLOGICSSEGMENTAL REVENUE
FIGURE 50 MASSBIOLOGICS: REGIONAL REVENUE
FIGURE 51 RENOVA THERAPEUTICS: KEY FINANCIALS
FIGURE 52 RENOVA THERAPEUTICS: SEGMENTAL REVENUE
FIGURE 53 RENOVA THERAPEUTICS: REGIONAL REVENUE
FIGURE 54 SHENZHEN SIBIONO GENETECH CO., LTD: KEY FINANCIALS
FIGURE 55 SHENZHEN SIBIONO GENETECH CO., LTD: SEGMENTAL REVENUE
FIGURE 56 SHENZHEN SIBIONO GENETECH CO., LTD: REGIONAL REVENUE